ABVC BioPharma Provides Update for Botanical ADHD Drug Study

ABVC BioPharma, Inc. (Nasdaq: ABVC) has provided an update on its Phase 2b clinical study evaluating a potential treatment for Attention Deficit Hyperactivity Disorder (ADHD). The company says that 60 subjects have been enrolled and 53 have now completed treatment in the eight-week study.

ABVC BioPharma Chief Executive Officer, Uttam Patil, Ph. D., said, “Our clinical trials continue to demonstrate that medicine derived from plants can have significant therapeutic benefits, often with few – if any – side effects when treating serious medical conditions.”


ABVC’s Phase 2b study is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the United States and Taiwan.

The company’s previous Phase 2a study successfully achieved the specified primary endpoints and was accepted by the FDA in October 2020.

The study’s subjects were enrolled at the UCSF Medical Center and five medical centers in Taiwan.

ABVC’s ABV-1505 is a botanical drug based on traditional Chinese Medicine and has shown no adverse effects or addiction in Phase I and Phase II Part 1 clinical studies.

According to the Polaris market research report, the global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030 with a CAGR of 7.1% over the forecast period.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. ABVC BioPharma’s network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.

Share This Article


About the Author

ABVC BioPharma Provides Update for Botanical ADHD Drug Study

Editor Prism MarketView